financetom
Business
financetom
/
Business
/
Ocugen Completes Dosing in Third Cohort in Trial of Stargardt Disease Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ocugen Completes Dosing in Third Cohort in Trial of Stargardt Disease Treatment
Aug 29, 2024 9:19 AM

07:16 AM EDT, 08/28/2024 (MT Newswires) -- Ocugen ( OCGN ) said Wednesday that it has completed dosing in the third cohort of its phase 1/2 clinical trial of OCU410ST, a modifier gene therapy candidate being developed for Stargardt disease.

Three subjects received a single subretinal injection of the highest dose being tested, the company said.

Price: 1.3800, Change: +0.05, Percent Change: +3.76

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nvidia overtakes Apple as No. 2 most valuable company
Nvidia overtakes Apple as No. 2 most valuable company
Jun 6, 2024
(Reuters) - Nvidia's ( NVDA ) rallied to record highs on Wednesday, with the artificial intelligence chipmaker's valuation breaching the $3 trillion mark and overtaking Apple ( AAPL ) to become the world's second most valuable company. Nvidia ( NVDA ) is preparing to split its stock ten-for-one, effective on June 7, a move that could increase its appeal to...
Preview: Rapport Therapeutics, Inc Set To IPO Tomorrow
Preview: Rapport Therapeutics, Inc Set To IPO Tomorrow
Jun 6, 2024
Rapport Therapeutics, Inc (NASDAQ:RAPP) IPO will take place June, 07 on the NASDAQ exchange under the ticker RAPP. The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on December 04, 2024. See also: Benzinga IPO Calendar About Rapport Therapeutics, Inc Rapport Therapeutics, Inc is a...
Why Five Below Shares Are Trading Lower Thursday
Why Five Below Shares Are Trading Lower Thursday
Jun 6, 2024
Five Below, Inc. ( FIVE ) stock is trading lower Thursday after the company reported worse-than-expected first-quarter earnings and cut guidance. The Details: Five Below ( FIVE ) announced first-quarter earnings for fiscal-year 2024 on Wednesday after the market closed. The specialty-value retailer reported adjusted EPS of 60 cents, missing analyst estimates of 63 cents, and sales of $811.86 million,...
Canopy Growth Sets up $250 Million At-the-Market Equity Program; Shares Fall
Canopy Growth Sets up $250 Million At-the-Market Equity Program; Shares Fall
Jun 6, 2024
11:17 AM EDT, 06/06/2024 (MT Newswires) -- Canopy Growth ( CGC ) said Thursday it has established a $250 million at-the-market equity program. The program allows the cannabis company to sell its common shares from time to time in concurrent public offerings in the US and Canada. The company said it plans to use any net proceeds from the program...
Copyright 2023-2026 - www.financetom.com All Rights Reserved